http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. </p><p> <b>Highlights</b> </p><p> “Under our previously announced License and Exclusive Distribution Agreement with NeoImmuneTech, Inc., or NIT, which became effective date on May 15, 2026, we granted NIT an exclusive license to our rights to market, sell, and distribute Endari and any generic equivalents we may develop in sickle cell disease in the U.S. and its http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26930330.html Fri, 14 Aug 2026 16:11:00 -0400 A.06822034 A.50202251 EMMA O.05242772 O.20026344 O.41729403 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Aug+14/26929380.html si-local-file:///var/storage/secattach/20260814/26929380.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Aug+14/26929380.html Fri, 14 Aug 2026 15:11:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Aug+14/26929380.html si-local-file:///var/storage/secattach/20260814/26929380.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+Aug+14/26929380.html Fri, 14 Aug 2026 15:11:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Jun+30/26928935.html si-local-file:///var/storage/secattach/20260814/26928935.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Jun+30/26928935.html Fri, 14 Aug 2026 14:22:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Jun+30/26928935.html si-local-file:///var/storage/secattach/20260814/26928935.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Emmaus+Life+Sciences%2C+++++For%3A+Jun+30/26928935.html Fri, 14 Aug 2026 14:22:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html si-local-file:///var/storage/secattach/20260515/26506424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html Fri, 15 May 2026 16:32:00 -0400 EMMA O.05242772 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html si-local-file:///var/storage/secattach/20260515/26506424.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Emmaus+Life+Sciences%2C+++++For%3A+May+15/26506424.html Fri, 15 May 2026 16:32:00 -0400 EMMA O.05242772 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Press+Releases/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741 http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html <p> TORRANCE, Calif.--(BUSINESS WIRE)-- <b>Emmaus Life Sciences, Inc. (OTCQB: EMMA)</b>,<b> </b>a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. </p><p> <b>Highlights</b> </p><p> “We realized an 18% decline in net revenues for three month ended March 31, 2026 as compared to the same period in 2025 primarily driven by a 33% decrease in U.S. sales amid ongoing competition from generic L-Glutamine. The decline was partially offset by a 94% increase in sales in the Middle East North Africa, http://www.streetinsider.com/Business+Wire/Emmaus+Life+Sciences+Reports+Quarterly+Financial+Results/26504486.html Fri, 15 May 2026 15:51:00 -0400 A.06822034 A.14320728 EMMA O.05242772 O.20026344 O.20250741